A Registered Observational Cohort Study of Myotonic Dystrophy Type 1

Key facts

Sponsor

First Affiliated Hospital of Fujian Medical University

Intervention

Triplet-primed PCR or Long-read sequencing(genetic)

Enrollment

300 enrolled

Eligibility

All sexes

Timeline

2008 – 2038

Study locations (1)

• First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Steinert myotonic dystrophy

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT06926621
  A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
  Vertex Pharmaceuticals Incorporated
• RECRUITINGPHASE1, PHASE2NCT06185764
  A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
  Vertex Pharmaceuticals Incorporated
• RECRUITINGPHASE1, PHASE2NCT05481879
  Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
  Dyne Therapeutics
• RECRUITINGNCT06075693
  Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
  Massachusetts General Hospital

See all trials for Steinert myotonic dystrophy →